INNOVATION. PRECISION. SCIENCE. SPEED.

Accelerating the development of first-in-class therapeutics against significant new drug targets to fight cancer.

Learn More

Clinical Trial

A multicenter Phase 1 clinical study (TACH101-CS-0001, NCT05076552) evaluating the safety, pharmacokinetics, and anti-tumor activity of TACH101, a first-in-class inhibitor of KDM4, in patients with advanced cancers is underway.

Learn More

Our Science

We are targeting new pathways and mechanisms to fight cancer at its core. We combine our deep scientific foundation in molecular cancer biology, tumorigenesis, and cancer stem cell biology, with expertise in preclinical and clinical drug development to advance novel therapeutics to treat advanced cancers.

Follow the Science

Innovators in Our Field

Tachyon operates with a dedicated internal core development team and a world-class external network of expertise to achieve one goal – advance our innovative programs with scientific rigor, speed and quality.

Meet the tachyon team

Accelerating Science for Breakthrough Therapies

KDM4

Lefty1

speed

Company News

June 2024

Tachyon Receives Orphan Drug Designation for KDM4i as a Treatment for Soft Tissue Sarcoma

March 2023

Tachyon featured in BioCentury and San Francisco Business Times

March 2023

Tachyon Announces Financing and Start of Clinical Study of First-in-Class KDM4 Inhibitor for Advanced Cancers

March 2023

Tachyon Receives Funding from CIRM for a Phase 1 Clinical Study of TACH101, a First-in-Class KDM4 Inhibitor, in Patients with Advanced Solid Tumors

August 2022

Tachyon Receives IND Clearance from FDA to Develop Novel KDM4 Inhibitor TACH101 for Advanced Solid Tumors

April 2022

Tachyon Presents Preclinical Data on the Company’s Novel KDM4 inhibitor, TACH101, at the 2022 AACR Annual Meeting

January 2022

Tachyon Presents TACH101 Data at the 2022 ASCO-GI Conference

October 2021

Tachyon Presents TACH101 Data at the 2021 AACR-NCI-EORTC Conference

September 2021

Tachyon Announces Presentation at the 2021 ESMO Annual Meeting

August 2021

Tachyon Announces Collaboration with AbCellera to Develop Novel Antibody Therapeutic Targeting TGF-β Superfamily Member for the Treatment of Cancer

June 2021

Tachyon announces presentations at the ASCO Annual Meeting

April 2021

Tachyon presents preclinical data on TACH101 at the AACR Annual Meeting.

2020

Tachyon completed seed funding and established fully operational organization.

2019

Tachyon founded by scientific inventors to advance KDM4 program for clinical development.